deltatrials
Completed PHASE1/PHASE2 INTERVENTIONAL 3-arm NCT01037088

Effects of Vaporized Marijuana on Neuropathic Pain

CCRC: The Analgesic Effect of Vaporized Cannabis on Neuropathic Pain

Sponsor: Center for Medicinal Cannabis Research

Conditions Multiple Sclerosis Neuropathic Pain Peripheral Neuropathy Post-herpetic Neuralgia Reflex Sympathetic Dystrophy Spinal Cord Injury
Interventions Cannabis Low dose cannabis Mild dose cannabis
Updated 9 times since 2017 Last updated: Jan 11, 2018 Started: Dec 31, 2009 Primary completion: Nov 30, 2012 Completion: Nov 30, 2012
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1/PHASE2 trial investigates Multiple Sclerosis and Neuropathic Pain and is currently completed. Center for Medicinal Cannabis Research leads this study, which shows 9 recorded versions since 2009 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Study Description(click to expand)

We conducted a double-blind, placebo-controlled, crossover study evaluating the analgesic efficacy of vaporized cannabis in subjects, the majority of whom were experiencing neuropathic pain despite traditional treatment. Thirty-nine patients with central and peripheral neuropathic pain underwent a standardized procedure for inhaling medium-dose (3.53%), low-dose (1.29%), or placebo cannabis with the primary outcome being visual analog scale pain intensity. Psychoactive side effects and neuropsychological performance were also evaluated.

We conducted a double-blind, placebo-controlled, crossover study evaluating the analgesic efficacy of vaporized cannabis in subjects, the majority of whom were experiencing neuropathic pain despite traditional treatment. Thirty-nine patients with central and peripheral neuropathic pain underwent a standardized procedure for inhaling medium-dose (3.53%), low-dose (1.29%), or placebo cannabis with the primary outcome being visual analog scale pain intensity. Psychoactive side effects and neuropsychological performance were also evaluated.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotCompleted~Feb 2017 – ~Feb 2018 · 12 months · monthly snapshotCompleted~Feb 2018 – ~Jun 2018 · 4 months · monthly snapshotCompleted~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshotCompleted~Jan 2021 – ~Dec 2021 · 11 months · monthly snapshotCompleted~Dec 2021 – ~Jul 2024 · 31 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – present · 19 months · monthly snapshotCompleted~Jan 2026 – present · 3 months · monthly snapshotCompleted

Change History

9 versions recorded

  1. Jan 2026 — Present [monthly]

    Completed PHASE1/PHASE2

  2. Sep 2024 — Present [monthly]

    Completed PHASE1/PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  4. Dec 2021 — Jul 2024 [monthly]

    Completed PHASE1_PHASE2

  5. Jan 2021 — Dec 2021 [monthly]

    Completed PHASE1_PHASE2

▶ Show 4 earlier versions

  1. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE1_PHASE2

  2. Feb 2018 — Jun 2018 [monthly]

    Completed PHASE1_PHASE2

  3. Feb 2017 — Feb 2018 [monthly]

    Completed PHASE1_PHASE2

  4. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE1_PHASE2

    First recorded

Dec 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Center for Medicinal Cannabis Research
  • University of California, Davis
  • VA Northern California Health Care System
Data source: University of California, Davis

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations